Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.48 |
| ▸ | CYP1A2 | P05177 | 4/20 | 0.48 |
| ▸ | CYP3A4 | P08684 | 4/20 | 0.48 |
| ▸ | CYP2D6 | P10635 | 4/20 | 0.48 |
| ▸ | CYP2C9 | P11712 | 4/20 | 0.48 |
| ▸ | CYP2C19 | P33261 | 4/20 | 0.48 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.48 |
| ▸ | MEN1 | O00255 | 1/20 | 0.48 |
| ▸ | STAT3 | P40763 | 1/20 | 0.48 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.48 |
| ▸ | GAA | P10253 | 1/20 | 0.47 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.47 |
| ▸ | CASR | P41180 | 9/20 | 0.43 |
| ▸ | GRM1 | Q13255 | 1/20 | 0.41 |
| ▸ | TSHR | P16473 | 2/20 | 0.39 |
| ▸ | CASP1 | P29466 | 2/20 | 0.39 |
| ▸ | CASP7 | P55210 | 2/20 | 0.39 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.39 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.39 |
| ▸ | CLK4 | Q9HAZ1 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5435338 | 0.99 | ALDH1A1 (0.50) | ALDH1A1CYP1A2CYP3A4CYP2D6CYP2C9 | |
| SCHEMBL5444100 | 0.98 | ALDH1A1 (0.46) | ALDH1A1CYP1A2CYP3A4CYP2D6CYP2C9 | |
| SCHEMBL5449155 | 0.96 | CASR (0.45) | ALDH1A1CYP1A2CYP3A4CYP2D6CYP2C9 | |
| SCHEMBL5440726 | 0.81 | CASR (0.47) | ALDH1A1CYP1A2CYP3A4CYP2D6CYP2C9 | |
| SCHEMBL5436798 | 0.81 | CASR (0.47) | SMN1; SMN2MEN1KMT2ACASRTP53 | |
| SCHEMBL5445685 | 0.81 | CASR (0.48) | SMN1; SMN2MEN1KMT2ACASRTP53 | |
| SCHEMBL5450352 | 0.81 | CYP1A2 (0.47) | ALDH1A1CYP1A2CYP3A4CYP2D6CYP2C9 | |
| SCHEMBL5441088 | 0.81 | CASR (0.52) | ALDH1A1SMN1; SMN2MEN1KMT2ACASR | |
| SCHEMBL5443722 | 0.79 | CASR (0.56) | CYP1A2CYP3A4CYP2C19MEN1KMT2A | |
| SCHEMBL5444271 | 0.79 | CASR (0.47) | SMN1; SMN2CASRTSHRTP53MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070270446-A1 | Reversed Pyrimidinone Compounds as Calcilytics | SMITHKLINE BEECHAM CORPORATION (US) | 2007-11-22 | — | — | US | claimed |
| US-20070270446-A1 | Reversed Pyrimidinone Compounds as Calcilytics | SMITHKLINE BEECHAM CORPORATION (US) | 2007-11-22 | — | — | US | disclosed |
| US-20070270446-A1 | Reversed Pyrimidinone Compounds as Calcilytics | SMITHKLINE BEECHAM CORPORATION (US) | 2007-11-22 | — | — | US | disclosed |
| US-20070270446-A1 | Reversed Pyrimidinone Compounds as Calcilytics | SMITHKLINE BEECHAM CORPORATION (US) | 2007-11-22 | — | — | US | disclosed |
| EP-1809611-A1 | REVERSED PYRIMIDINONE COMPOUNDS AS CALCILYTICS | NPS PHARMACEUTICALS, INC. (US) | 2007-07-25 | — | — | EP | disclosed |
| WO-2006041968-A1 | REVERSED PYRIMIDINONE COMPOUNDS AS CALCILYTICS | NPS PHARMACEUTICALS, INC. (US) | 2006-04-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070270446-A1 | Reversed Pyrimidinone Compounds as Calcilytics | PTMS, CALCR, TYMP | ALDH1A1 3806/4885CYP1A2 4087/4885CYP3A4 3494/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.